Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Applications of biopolymers for drugs and probiotics delivery
This post hoc analysis was determined to be exempt from institutional review board review by WCG IRB under 45 CFR 46.104(d)(4)
Ultomiris (ravulizumab-cwvz) Indication(s): Multiple rare, complement-mediated disorders, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD) Manufacturer(s): Alexion/AstraZeneca 2024 Sales: $3.92 billion Why it sold so well: Ultomiris, developed by Alexion, AstraZeneca Rare Disease, is emerging as a hematology drug to watch in 2025, driven by strong commercial momentum and expanding clinical uptake in 2024
BioPerine enhances the absorption of many substances, which is beneficial for nutrients but potentially problematic for medications
Immunofluorescence analysis was performed with anti-Myc, anti-Tom20, and anti-Calnexin antibodies to visualize the localization of TurboID-MITOL, mitochondria, and ER, respectively
We used danuglipron for these experiments because its fast-onset kinetics facilitated temporal alignment between drug administration, feeding assays and fibre photometry recordings, enabling more precise interpretation of region-specific GLP1R activation 7,8,9
